No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
C4 Therapeutics Gains After Portfolio Updates
Express News | C4 Therapeutics: Cash Runway Expected to Fund Operations Into 2027
Express News | C4 Therapeutics: Data in Melanoma & Colorectal Cancer Expected in Second Half of 2025
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?